AbClon Inc. (KOSDAQ:174900)

South Korea flag South Korea · Delayed Price · Currency is KRW
40,000
-1,400 (-3.38%)
At close: Dec 5, 2025
187.77%
Market Cap 763.72B
Revenue (ttm) 3.80B
Net Income (ttm) -16.23B
Shares Out 19.09M
EPS (ttm) -896.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 367,492
Average Volume 471,599
Open 41,450
Previous Close 41,400
Day's Range 38,900 - 42,200
52-Week Range 6,810 - 43,000
Beta 0.99
RSI 68.72
Earnings Date n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 174900
Full Company Profile

Financial Performance

In 2024, AbClon's revenue was 2.34 billion, a decrease of -18.67% compared to the previous year's 2.88 billion. Losses were -16.42 billion, 27.2% more than in 2023.

Financial Statements

News

There is no news available yet.